信必可COMPASSCN.pptVIP

* In addition to number of events; Total numbers of days with event (number of days due to hosp/ER visits): Seretide: 1327 (278) 2 x Symbicort: 1143 (174) 维持缓解治疗: 692 (108) * Summary table for severe exacerbation data. 维持缓解治疗 vs Seretide: statistical significance for all exacerbations and hosp/ER treatments 维持缓解治疗 vs 2 x Symbicort: statistical significance for all exacerbations 2 x Symbicort vs Seretide: statistical significance for the hosp/ER rate * Both 维持缓解治疗 and fixed Symbicort are superior to Seretide comparing the rate of hosp/ER * Run-in values for the whole population marked on the y-axis. Number of patients with at least one exacerbation are presented in the box. * Very good improvements in Asthma control days for all groups. Treatment means (run-in) % of days: Seretide: 43.7 (5.7) 2 x Symbicort: 42.2 (5.9) 维持缓解治疗: 41.3 (5.8) * Reliever run-in: 2.3 inh/day PEF run-in: 335-338 L/min * Similar good improvement for all groups. * Reliever use: Median during run-in is 2.0 inh/day and the median is 0.5-0.6 inh/day during treatment. This illustration is called a box and whisker plot and shows the distribution of mean daily reliever use. * Fewer patients in the 维持缓解治疗 group used 4 or 8 inh/day for more than 10 days. * ICS dose is also presented as BDP equivalents. This way to compare doses between different steroids is used in GINA. Use of oral steroids due to asthma is presented. The level of ICS and oral steroids are lower with 维持缓解治疗 compared to the other treatments. FP=Fluticasone propionate BUD=Budesonide COMPASS 研究 Kuna et al, International Journal of Clinical Practice 2007;61(5):725-736. 仅供内部使用 研究目的 信必可维持、缓解治疗的疗效和安全性与以下治疗方法相比: 双倍的信必可维持剂量 舒利迭TM最常使用的处方剂量 SYMBICORT 维持缓解治疗 and BRICANYL are trade marks of the AstraZeneca group of companies The trademark SERETIDE is owned by GlaxoSmithKline 筛选期 COMPASS: 研究设计 沙美特罗/氟替卡松25/125 μg 2 吸 bid + 博利康尼 作为缓解药物 n=1123 信必可 320/9 μg 1 吸 bid + 博利康尼 作为缓解药物